Lepu Biopharma Co., Ltd. (HKG:2157)
Hong Kong · Delayed Price · Currency is HKD 3.735
-0.225 (-5.68%)
Sep 11, 2026, 4:08 PM HKT
Lepu Biopharma Revenue
Lepu Biopharma had revenue of 522.41M CNY in the half year ending June 30, 2026, with 291.96% growth. This brings the company's revenue in the last twelve months to 991.34M, up 41.53% year-over-year. In the year 2025, Lepu Biopharma had annual revenue of 934.87M with 154.18% growth.
Revenue (ttm)
991.34M CNY
Revenue Growth
+41.53%
P/S Ratio
5.89
Revenue / Employee
1.53M CNY
Employees
646
Market Cap
6.74B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 934.87M | 567.08M | 154.18% |
| Dec 31, 2024 | 367.79M | 142.44M | 63.21% |
| Dec 31, 2023 | 225.35M | 209.78M | 1,347.16% |
| Dec 31, 2022 | 15.57M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.52B |
| Shanghai Haohai Biological Technology | 2.68B |
| Alphamab Oncology | 598.06M |
| Suzhou Ribo Life Science | 536.18M |
| CStone Pharmaceuticals | 490.92M |
| CARsgen Therapeutics Holdings | 157.72M |
| GenFleet Therapeutics (Shanghai) | 144.96M |
| Abbisko Cayman | 112.29M |
Lepu Biopharma News
- 23 days ago - Lepu Biopharma Reports Revenue Growth As Oncology Pipeline Advances - Nasdaq
- 6 weeks ago - AstraZeneca's Sone-Ve Improves Survival In Gastric Cancer Trial - Nasdaq